Independent ASCs are declining after decades of sinking reimbursement rates and soaring operational costs have forced ASC ...

Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc.